Holen Sie sich die Stockscreener-App
15.22
0.13%
0.02
Handel nachbörslich:
15.22
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
How to recover losses in Immunovant Inc. stockJuly 2025 Retail & Risk Managed Investment Signals - Newser
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus - MSN
Technical Bounce Expected in Immunovant Inc. Next WeekDividend Hike & Weekly Setup with High ROI Potential - thegnnews.com
Immunovant, Inc. shares fall 3.83% intraday after law firm investigation announcement. - AInvest
Immunovant shares fall 5.54% premarket after law firm investigation announcement. - AInvest
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc.IMVT - The Globe and Mail
Immunovant Reports Progress and Financial Results - TipRanks
Immunovant price target lowered to $57 from $58 at Citi - MSN
Immunovant Receives Buy Rating from Guggenheim with $44 Price Target - AInvest
IMVT: Analyst Jason Gerberry Lowers Price Target to $30, Maintains 'Buy' Rating - AInvest
Immunovant's Q1 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Chart Patterns Forming a Bullish Setup in Immunovant Inc.Reliable Investment Entry Signals Confirmed by Charts - sundaytimes.kr
What makes Immunovant Inc. stock price move sharplyWealth Tripler Trade List - newsyoung.net
Immunovant Spends More To Move Key Drug Trials Forward - Finimize
Immunovant Pours More Into Trials And Investors Aren’t Flinching - Finimize
Immunovant Posts 34% R&D Jump in Q1 - AOL.com
Stifel lowers Immunovant stock price target to $50 from $61, maintains Buy - Investing.com Canada
Assessing Immunovant's Strategic Expansion and Financial Viability Amid Widening Losses - AInvest
Immunovant's Fiscal Q1 Net Loss Widens - MarketScreener
Immunovant Posts 34% R&D Jump in Q1 - The Motley Fool
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
Immunology company Immunovant's Q1 net loss widens to $120.6 mln - MarketScreener
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 - The Manila Times
Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News - Stock Titan
Candlestick Reversal Detected on Immunovant Inc.’s ChartReal Time Alerts Based on AI Prediction Triggered - metal.it
Is Immunovant Inc. a growth stock or a value stockStrong return on investment - Jammu Links News
How does Immunovant Inc. compare to its industry peersAchieve rapid portfolio appreciation today - Jammu Links News
What are the technical indicators suggesting about Immunovant Inc.Massive wealth growth - Jammu Links News
Is Immunovant Inc. a good long term investmentFastest-growing stock picks - Jammu Links News
Should I hold or sell Immunovant Inc. stock in 2025Sky-high return potential - Jammu Links News
When is Immunovant Inc. stock expected to show significant growthTriple-digit growth rates - Jammu Links News
How volatile is Immunovant Inc. stock compared to the marketUnmatched market gains - Jammu Links News
What drives Immunovant Inc. stock priceCapitalize on market opportunities with confidence - Jammu Links News
What institutional investors are buying Immunovant Inc. stockOutperformance with explosive growth - Jammu Links News
Is it the right time to buy Immunovant Inc. stockFree Stock Movement Tracking - Jammu Links News
What catalysts could drive Immunovant Inc. stock higher in 2025Breakthrough wealth creation - Jammu Links News
Is Immunovant Inc. stock overvalued or undervaluedBuild a portfolio that outperforms the market - Jammu Links News
What are analysts’ price targets for Immunovant Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
How does Immunovant Inc. generate profit in a changing economyFree Capital Growth Strategies - Jammu Links News
What analysts say about Immunovant Inc. stockCapitalize on market momentum for big wins - Jammu Links News
How many analysts rate Immunovant Inc. as a “Buy”Get daily updates on top-performing stocks - Jammu Links News
Why is Immunovant Inc. stock attracting strong analyst attentionMaximize gains with expert trading strategies - Jammu Links News
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Immunovant Appoints Eric Venker as New CEO - The Globe and Mail
Immunovant appoints Eric Venker as CEO with new compensation agreement By Investing.com - Investing.com Canada
Momentum Screeners Rank Immunovant Inc. in Top 5 TodayReversal Alert Based on RSI Indicator Confirmed - metal.it
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):